Key terms
About CGTX
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CGTX news
Apr 16
7:41am ET
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Apr 12
7:45am ET
Cognition Therapeutics to hold a conference call
Apr 12
4:55am ET
Cognition Therapeutics to hold a conference call
Mar 28
7:35am ET
Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials
Mar 11
8:19pm ET
Cognition Therapeutics 6.57M share Spot Secondary priced at $1.75
Mar 11
4:08pm ET
Cognition Therapeutics files to sell common stock, no amount given
Mar 06
7:41am ET
Cognition Therapeutics presents analyses at AD/PD 2024
Feb 22
7:54am ET
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)
Feb 20
5:03pm ET
Cognition Therapeutics Rewards Executives with Stock for Milestones
Feb 06
8:50am ET
Cognition Therapeutics identifies key proteins involved in Alzheimer’s disease
No recent press releases are available for CGTX
CGTX Financials
Key terms
Ad Feedback
CGTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CGTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
